Epstein-Barr Virus
EBV-induced growth proliferation inhibited by nuclear antigen EBNA2-TAT peptide
Published in Gene Therapy Weekly, June 17th, 2004
"Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with cancers in immunocompromised populations. Antiviral drugs targeted against lytic viral replication have limited efficacy in these disease settings. EBV infection of peripheral blood mononuclear cells induces growth proliferation and the EBV latency Epstein-Barr virus-encoded nuclear antigen (EBNA)2 transcriptional transactivator (TAT) is essential for this response," scientists writing in the journal Proceedings of the National Academy of Sciences USA report.
"EBNA2...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-06-17)
More Articles from Gene Therapy Weekly
- Acute Lymphoid Leukemia
Combinatorial gene therapy offers antitumor protection to leukemia models - Bioengineering
A novel genetically engineered marker keeps track of stem cells in vivo - Restenosis
Implanted stents with c-myc suppressant engender arterial healing - Transplant Medicine
Hepatocyte growth factor expands outcomes after islet transplantation - Vector Development
Herpesvirus-based vector systems provide for efficient transduction - AIDS Therapy
Researchers explore gene treatment to obliterate HIV before it does damage - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
